Lana Pine

Adverse events were significantly more frequently reported by pregnant patients when compared with non-pregnant patients. However, no differences were observed when comparing pregnant patients with autoimmune disease and healthy controls.

The results of the study provide a proof of concept for upadacitinib treatment in patients with systemic lupus erythematosus.

Patients treated with upadacitinib maintained greater improvements in SLE disease activity, lupus flares, and time to first flare when compared with the placebo cohort.

Data indicate dazodalibep has the potential to address unmet therapeutic needs for patients with Sjögren’s syndrome.

The biosimilars were equivalent with the biologic regarding both ACR20 response achievement and change of Health Assessment Questionnaire-Disability Index (HAQ-DI) scores at month 6.

At the 12-month mark, opioid discontinuation occurred in 29% of patients in the intervention cohort compared with only 7% in the usual care group.

Janssen's efforts are accompanied by extensive data generation in patients of color and the creation of a diverse workforce.

In today’s episode, we explore how the lived experience of someone with rheumatoid arthritis can systematically be documented via the use of patient-reported outcome measures.

The podcast will explore the personal experiences of people living with rheumatic diseases and the latest research evidence that informs their diagnosis and treatment.

Janssen aims to address health inequities and promote culturally competent care.

The disparities compelled them to launch Determi-Nation, which utilizes healthcare providers, advocates, and patients within the psoriatic disease community to co-create solutions that address the observed inequities.

The approval was based on a comprehensive assortment of studies which showed adalimumab-aaty was comparable to the reference product, adalimumab.

The approval was based on data from a pharmacodynamic study which showed nalmefene provided a fast onset of reversal of respiratory depression from the synthetic opioid remifentanil.

The US Food and Drug Administration (FDA) has approved the adalimumab-adbm (Cyltezo) autoinjector pen ahead of the July 1 commercial launch.

Statistically significant improvements were observed in all 10 PROMIS domains analyzed.

The analyses emphasized the early and sustained resolution of enthesitis through 52 weeks with both adalimumab and secukinumab.

A fibromyalgia diagnosis was significantly associated with GERD, IBS, Crohn’s disease, ulcerative colitis, and celiac disease.

Significant improvements in pain intensity, health-related quality of life, and depression were observed in patients receiving an online pain management intervention.

At the 12-week mark, the change from baseline in the DAS28-CRP was significantly greater in patients with rheumatoid arthritis receiving 700 mg peresolimab when compared with the placebo group.

At the 2-year mark after methotrexate initiation, 71% of patients with psoriatic arthritis and 76% of patients with rheumatoid arthritis remained on methotrexate.

Patients with fibromyalgia reported significantly less recreational, transportation-related, and total physical activity levels when compared with controls.

In addition to demonstrating efficacy, the numbers and incidence rates of treatment-emergent adverse events and treatment-emergent infections decreased throughout the 10-year follow-up.

Pooled results proved that telerehabilitation improved the Fibromyalgia Impact Questionnaire score and quality of life in patients with fibromyalgia when compared with controls.

During the study follow-up period, 74.5% of switchers and 51.3% of infliximab-naïve patients remained on ABP 710 treatment without a treatment gap.

The primary pharmacokinetic analysis proved equivalence between MSB11022-acetate and adalimumab.

The sensitivity for colorectal cancer detection of the blood-based test was 83%, meeting the co-primary sensitivity endpoint.

The mean number of required reinterventions was significantly lower in the patients who received a direct endoscopic necrosectomy at index session when compared with patients who received the step-up treatment approach.

Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.

Rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and ustekinumab.

Patients with IBD who were treated with advanced therapies who obtained clinical remission had 1.6 times more likely to maintain remission when compared with those who achieved clinical response without remission.